Wolfgang Plischke, Bayer's chief of innovation, will be retiring at the end of this month after over 30 years at Bayer. During his time at the German pharmaceutical powerhouse, he has overseen its interests in pharmaceuticals, diagnostics and consumer health, both globally and regionally in North America and Japan. He discusses research and development (R&D) funding and the intersection of human, animal and plant research with Asher Mullard.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Wolfgang Plischke. Nat Rev Drug Discov 13, 252 (2014). https://doi.org/10.1038/nrd4285
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4285
